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With increasing life expectancy, Alzheimer’s disease (AD) and other types of age-associated dementia are on the rise worldwide.
Treatment approaches for dementia are insufficient and novel therapies are not readily available. In this context repurposing
of established drugs appears attractive. A well-established class of cardiovascular drugs, which targets the angiotensin II
system, is such a candidate, which currently undergoes a paradigm shift with regard to the potential benefit for treatment of
neurodegenerative symptoms. In search for additional evidence, we subjected aged rats to chronic unpredictable mild stress,
which is known to enhance the development of AD-related neuropathological features. We report here that four weeks of chronic
mild stress induced a strong upregulation of the hippocampal angiotensin-converting enzyme (Ace) at gene expression and
protein level. Concomitantly, tau protein hyperphosphorylation developed. Signs of neurodegeneration were detected by the
significant downregulation of neuronal structure proteins such as microtubule-associated protein 2 (Map2) and synuclein-gamma
(Sncg). Ace was involved in neurodegenerative symptoms because treatment with the brain-penetrating ACE inhibitor, captopril,
retarded tau hyperphosphorylation and signs of neurodegeneration.Moreover,ACE inhibitor treatment could counteract glutamate
neurotoxicity by preventing the downregulation of glutamate decarboxylase 2 (Gad2). Taken together, ACE inhibition targets
neurodegeneration triggered by environmental stress.
1. Introduction
Alzheimer’s disease (AD) is the most common form of
dementia.While genetic factors are causally linked to familial
AD, the pathogenesis of the predominant late-onset sporadic
AD is diverse and less defined. Age is one of the best-
documented risk factors for sporadic AD, which acts in con-
cert with a wide array of brain insult-promoting vascular and
metabolic factors such as hypertension, ischemia, diabetes,
high cholesterol, and different forms of environmental stress
and stress-related psychiatric symptoms, that is, depression
and anxiety [1–3].
Experimental models of AD often reproduce genetic
alterations whereas the impact of additional brain-damaging
factors is more difficult to assess. The chronic unpredictable
mild stress (CUMS) model imitates psychiatric risk factors
such as psychological, psychosocial, and physical stress [4].
In agreement with the well-established impact of stress on
neuronal viability, the model promotes signs of neuronal
degeneration such as decreased synaptic transmission at
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hippocampal CA1-CA3 synapses, impaired neurogenesis, and
cognitive dysfunction [5–7]. The sensitivity to stress in this
model increases with age, a major factor of AD pathogenesis
[8]. The relationship to AD is further supported by several
studies, which show that the CUMS procedure worsens
disease progression in genetic AD mouse models [9–11].
Moreover, the chronic mild stress protocol induces major
neuropathological hallmarks of AD, that is, enhanced 𝛽-
amyloid (A𝛽) generation, tau hyperphosphorylation, and the
appearance of various other AD markers [9, 11, 12]. In this
respect, the chronic mild stress model could complement
genetic ADmodels because the CUMSmodel solely relies on
endogenously expressed proteins. In view of the recent failure
of large clinical trials, which targeted 𝛽-amyloid plaques
[13, 14], such alternative models, which imitate the disease
process before the accumulation ofA𝛽plaques, could become
of substantial value.
Inefficient A𝛽 plaque-targeting approaches also raise the
necessity to identify players in AD pathogenesis, which could
interrupt the disease process at an earlier stage [15]. For
one player in AD pathogenesis a paradigm shift is currently
on the way, which is the angiotensin system, notably the
angiotensin-converting enzyme (ACE). While many studies
considered ACE primarily as an enzyme that could promote
proteolysis of 𝛽-amyloid in vitro [16–18], recent experimental
and clinical studies provide strong evidence that inhibition
of ACE-dependent angiotensin II generation in vivo could
actually reduce signs of neurodegeneration in experimental
ADmodels [19, 20] and slow the cognitive decline of patients
with Alzheimer’s disease [21–25].
In view of this emerging development, we aimed to
further analyse the impact of ACE inhibition on early signs
of neurodegeneration and applied the chronic unpredictable
mild stress model in our study.
2. Materials and Methods
2.1. Chronic Unpredictable Mild Stress Model. Male Wistar
rats (15 months of age) were subjected to the chronic
unpredictable mild stress (CUMS) battery for four weeks.
The CUMS protocol was performed essentially as described
previously [8, 9]. After four weeks of stress, more than 90%
of stressed rats showed signs of anhedonia as documented
by a decrease in sucrose preference compared to nonstressed
controls (i.e., <50% of sucrose consumption compared to
nonstressed controls). The age-matched control group was
housed under standard conditions and had free access to food
and water. The captopril treatment group received captopril
in drinking water (50mg/kg/day, dissolved fresh every day)
during the CUMS protocol. After 28 days of stress, at an
age of 16 months, 4 h before the beginning of the dark
phase, rats were anesthetized with ketamine and xylazine
(100mg/kg and 10mg/kg, i.p.), and brains were removed and
processed for immunohistology [9, 20]. For whole genome
microarray gene expression profiling, biochemical analyses,
and immunoblotting, the hippocampus was dissected out on
ice and processed for further use as detailed below.
All animal experiments were performed in accordance
with the NIH guidelines and were approved by the local
committee on animal research (MRC, Ain Shams University
Hospitals, Cairo, Egypt).
2.2. Whole Genome Microarray Gene Expression Profiling of
Hippocampal Gene Expression. For whole genome microar-
ray gene expression analysis, total hippocampal RNA was
isolated from stressed rats and age-matched nonstressed
control rats. Total RNA was processed for whole genome
microarray gene expression profiling and hybridized to the
GeneChip Rat Genome 230 2.0 Array (more than 31 000
probe sets, Affymetrix) as detailed previously [20]. The total
RNA from 3 animals was pooled for one gene chip, and
two gene chips are presented for each group. Microarrays
were scanned with the Affymetrix GeneChip Scanner 7G,
and signals were processed with a target value of 300 using
GCOS (version 1.4, Affymetrix). Applied selection criteria for
differently expressed genes (2-fold change requirement, just
alpha, no false discovery correction, and 𝑃 < 0.05) were vali-
dated specifically for drug treatment effects [20] and follow
the guidelines of the Microarray Quality Control (MAQC)
project for the identification of reproducible gene lists [26,
27]. Probe sets with significant difference (𝑃 < 0.05 and
≥2-fold difference, with call present and/or signal intensity
≥100) between stressed rats and nonstressed, age-matched
control rats were used for GO classification. Microarray data
are available at the NCBI GEO repository (GSE72062).
Gene expression of Ace and Map2 in the hippocampus
of stressed rats and nonstressed controls was determined by
real-time quantitative (q) RT-PCR with a LightCycler 480
(Roche Diagnostics). Sequences of the forward and reverse
primers were as follows: Ace forward 5󸀠-GATTGCAGC-
CGGGCAACTTTTC-3󸀠; Ace reverse 5󸀠-CGGATCCGA-
TGATCCTTCGC-3󸀠;Map2 forward 5󸀠-CACTGGAAGAAG-
CCTCGAAGA-3󸀠; Map2 reverse 5󸀠-CACGGGCATTTC-
GATGAACC-3󸀠.
2.3. Immunoblotting, Immunohistology, and Biochemical
Methods. Immunoblot detection of hippocampal proteins
was performedwith hippocampal tissue extracts as described
[9, 20]. For immunohistology and immunofluorescence
analysis, we used paraffin-embedded brain sections obtained
from stressed and nonstressed rats (8𝜇m, taken at 50𝜇m
intervals, 10–15 sections per set). The following antibodies
were used for immunoblotting, immunofluorescence, and
immunohistology: anti-Ace antibodies raised in rabbit
against an antigen corresponding to amino acids 720–750
of mouse Ace [20]; anti-angiotensin II antibodies raised in
rabbit against synthetic angiotensin II [20]; anti-APP/A𝛽
antibodies raised in rabbit against a peptide corresponding
to amino acids 672–714 of human APP [20]; anti-AT1R
antibodies raised in rabbit against an antigen corresponding
to amino acids 306–359 of the mouse Agtr1a sequence
[20]; anti-Gad65 antibody (clone N-GAD65, developed in
mouse against a synthetic peptide corresponding to amino
acids 4–22 of human GAD65); anti-Grin3a antibodies
raised in rabbit against a synthetic peptide derived from
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Figure 1: Chronic unpredictable mild stress induced upregulation of hippocampal Ace protein and gene expression. (a) Immunohistological
localization of Ace in a brain vessel of a stressed rat. Nuclei were stained with hematoxylin (HE); bar: 20 𝜇m. (b) Immunofluorescence
localization of Ace (red) and the pericyte marker Ng2 (green) in a brain vessel of a stressed rat. Ace was detected with affinity-purified
rabbit anti-Ace antibodies followed by F(ab)
2
fragments of Alexa Fluor 546-labeled (red) secondary antibodies, and Ng2 was detected with
affinity-purified murine anti-NG2 antibody followed by F(ab)
2
fragments of Alexa Fluor 488-labeled (green) secondary antibodies. Nuclei
were stained with DAPI (bar: 20 𝜇m). (c) Immunohistological localization of Ace in hippocampal CA3 neurons of a stressed rat (left) relative
to a nonstressed control (right). Nuclei were stained with hematoxylin (HE); bar: 20 𝜇m. Histological experiments are representative of 4
rats/group (a–c). (d) Hippocampal Ace gene expression was determined by qRT-PCR and is presented as the ratio of Ace/Gapdh expression
(±s.d.; 𝑛 = 4; 𝑃 = 0.0011). (e) Immunoblot detection of the hippocampal Ace protein with anti-Ace antibodies in stressed rats relative to
nonstressed controls (𝑛 = 4/group). (f) Hippocampal Ace activity of stressed rats relative to nonstressed controls (i.e., 100%; ±s.d., 𝑛 = 8;
𝑃 = 0.0001). (g) The hippocampal angiotensin II content was determined by immunoblot in stressed rats relative to nonstressed controls
(upper panel). The lower panel shows a control immunoblot, which detects Gnb (𝑛 = 4/group).
the extracellular domain of rat Grin3a (Abcam); anti-MAP2
mouse monoclonal antibody generated against bovine mi-
crotubule-associated protein, MAP2 (Clone AP-20); anti-
chondroitin sulfate proteoglycan NG2 mouse monoclonal
antibody generated against a truncated form of NG2
(MAB5384); anti-PHF-tau pSer202 and pThr 205 antibody
(mouse monoclonal antibody, clone AT8; Pierce); and anti-
Sncg antibodies raised in goat against an internal region of
human SNCG (Santa Cruz Biotechnology).
HippocampalAce activity was assessed with a fluorogenic
substrate (Abz-FRK(Dnp)-P; Biomol) as described [20], and
determination of hippocampal glutamic acid decarboxylase
(Gad) enzyme activity was performed as detailed previously
[8].
2.4. Statistical Analysis. The results are presented as means
± s.d. We used unpaired two-tailed Student’s 𝑡-test for
comparisons between two groups. Statistical significance was
set at a 𝑃 value of <0.05, unless otherwise specified.
3. Results
3.1. Chronic Unpredictable Mild Stress Induced Upregulation
of Hippocampal Ace Protein and Gene Expression. Chronic
stress worsens the progression of AD in patients and
transgenic disease models [9–11] but underlying mecha-
nisms are incompletely understood. Because the angiotensin-
converting enzyme (ACE) is upregulated in brains of AD
patients and mice [20], we asked for an interrelationship
between Ace and stress. We used the chronic unpredictable
mild stress model to investigate the role of Ace in stress-
induced signs of neurodegeneration. Initially, we analysed
the localization of Ace in stressed and nonstressed rat
brain. Complementary to previous data with AD mice [20],
endothelial cells lining a brain vessel of a stressed rat showed
strong immunostaining for Ace (Figure 1(a)). Immunoflu-
orescence localization of the pericyte marker, chondroitin
sulfate proteoglycan Ng2, indicated that Ace was predomi-
nantly present in vascular endothelial cells whereas adjacent
pericytes showed weaker staining for Ace (Figure 1(b)).
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We further investigated the localization ofAce by immun-
ohistology and focused on the hippocampal area because
chronic mild stress induces profound changes at hippocam-
pal CA3-CA1 synapses [7], that is, the brain area, which is
highly susceptible to AD-related neuronal damage. In agree-
ment with previous results [20], immunohistology analysis
detected Ace immunoreactivity in cell bodies of hippocampal
CA3 neurons (Figure 1(c)). Moreover, immunohistology
revealed a strong increase in Ace immunoreactivity in hip-
pocampal CA3 neurons of a stressed rat relative to that of a
nonstressed control (Figure 1(c)).
In agreement with the increased Ace immunoreactivity,
the gene expression level of hippocampal Acewas also signif-
icantly increased in stressed rats, that is, the hippocampalAce
gene expression level was 2.72 ± 0.43-fold higher in stressed
rats compared to that in nonstressed controls (𝑃 = 0.0011;
Figure 1(d)). Concomitantly, with Ace gene expression, the
increased hippocampal Ace protein level of stressed rats
was detected in immunoblot (Figure 1(e)). The increase in
Ace protein was accompanied by a significantly elevated
hippocampal Ace activity; that is, the hippocampal Ace
activity was 2.09 ± 0.24-fold higher (𝑃 = 0.0001) in stressed
rats compared to that in nonstressed controls (Figure 1(f)).
The elevated Ace activity was also reflected by an increased
hippocampal angiotensin II content in stressed rats relative
to nonstressed controls (Figure 1(g)). Taken together, chronic
unpredictable mild stress led to a significant upregulation
of the Ace protein in the hippocampal area of stressed rats.
As a consequence of Ace upregulation, the hippocampal
angiotensin II content in stressed rats was elevated compared
to that in nonstressed controls.
3.2. Tau Hyperphosphorylation in the Hippocampus of Stressed
Rats. The strong upregulation of Ace in the hippocampus of
stressed rats prompted us to search for signs of hippocampal
neurodegeneration because previous data showed a causal
relationship between Ace upregulation and signs of neurode-
generation in a genetic model of AD [20]. In this context
we determined the level of tau hyperphosphorylation as a
hallmark of AD. Immunohistological analysis demonstrated
that four weeks of chronic unpredictable mild stress induced
a strong increase in the level of phosphorylated tau pro-
tein in the hippocampus of an aged rat, as detected in a
hippocampal section with anti-PHF (AT8) antibody (Fig-
ure 2(a)). Immunohistology also revealed that the increased
tau phosphorylationwas predominant in neurons of the CA1-
CA3 region (Figure 2(a)). In contrast, PHF antibody staining
was negligible in hippocampal neurons of the nonstressed
control (Figure 2(a)).
Immunoblot detection of phosphorylated tau in hip-
pocampal tissue extracts confirmed the immunohistology
data and showed an increased level of hyperphosphorylated
tau protein in stressed rats compared to that in nonstressed
controls (Figure 2(b)). As an additional control, the total
level of hippocampal tau protein was not different between
stressed and nonstressed rats (Figure 2(b), lower panel).
Taken together, the upregulation of Ace and angiotensin II
in hippocampal neurons of stressed rats was accompanied by
tau hyperphosphorylation.
Ace-dependent angiotensin II generation promotes signs
of hippocampal neurodegeneration by activation of the AT1
receptor (AT1R) in a genetic ADmodel [20]. Complementary
to those data, immunofluorescence analysis of a stressed rat
brain showed AT1R immunoreactivity in hippocampal CA1
neurons, which also displayed accumulation of hyperphos-
phorylated tau protein (Figure 2(c)). Concomitantly, neu-
ronal loss of a highly PHF-positive CA1 neuron was detected
(Figure 2(c)). Thus, stress promoted Ace-dependent release
of the AT1R-stimulating angiotensin II peptide together with
tau hyperphosphorylation in hippocampal AT1R-positive
neurons.
3.3. Whole Genome Microarray Gene Expression Profiling
Detected Stress-Induced Signs of Hippocampal Neurodegen-
eration. We further investigated the impact of stress on
signs of neurodegeneration and performed whole genome
microarray gene expression profiling of hippocampal gene
expression. Gene ontology (GO) analysis searched for differ-
ently expressed neuron-specific genes by applying neuron-
specific GO terms, that is, neuron, axon, dendrite, and
synapse. Following established selection criteria for signif-
icantly different probe sets (≥2-fold difference and 𝑃 <
0.05), the GO analysis documented that stress triggered the
significant downregulation of neuron-specific genes, which
were categorized according to the cellular localization of
the respective proteins, that is, cytoplasm and membrane
(Figures 3(a) and 3(b)).
The list of significantly downregulated genes encompass-
es major neuronal structure proteins such as microtubule-
associated protein 2 (Map2) and synuclein-gamma, Sncg
(Figure 3(a)). Because the loss of neuronal Map2 is a char-
acteristic feature of AD-related neurodegeneration, which is
causally linked to stress-induced tau hyperphosphorylation
[9, 28], we performed immunolocalization of the hippocam-
palMap2. Immunohistology analysis detected the decreased
Map2 content in hippocampal CA1 neurons of a stressed rat
compared to that of a nonstressed control (Figure 3(c)). The
stress-induced downregulation of the hippocampal Map2
protein was further confirmed by qRT-PCR (Figure 3(d)).
Together these data indicate that chronic unpredictable mild
stress led to tau hyperphosphorylation and decreased the
level of neuron-specific genes such as Map2. The decreased
expression of neuronal structure proteins complements pre-
vious data, which show that chronic mild stress triggers
alterations of hippocampal synapses and promotes a decrease
in dendritic spine density [7].
The expression of glutamic acid decarboxylase 2 (Gad65/
Gad2) was also downregulated by chronic unpredictablemild
stress (Figure 3(a)). The decreased Gad65 expression could
account for the significantly decreased hippocampal Gad
enzyme activity, which was measured in hippocampal tissue
extracts of stressed rats compared to that of nonstressed
controls (Figure 3(e)). The ensuing decreased metabolism of
the excitatory neurotransmitter, glutamate, could be partially
responsible for the increased tau phosphorylation under
chronic mild stress [8, 29]. In addition to the decreased
glutamate degradation, the expression of the inhibitory and
BioMed Research International 5
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Figure 2: Tau hyperphosphorylation in the hippocampus of stressed rats. (a) Immunohistological detection of the hyperphosphorylated tau
protein (anti-PHF) in the hippocampus of a stressed rat (left panel) relative to a nonstressed control (right panel). Nuclei were counterstained
with hematoxylin (HE; bar: 200𝜇m). (b) Immunoblot detection of hyperphosphorylated tau in hippocampal extracts of stressed rats relative
to nonstressed controls was performed with anti-PHF antibody (IB: PHF (AT8)). The lower panel is a control immunoblot detecting total
tau protein (𝑛 = 4/group). (c) Immunofluorescence localization of AT1R (green) and PHF (red) in hippocampal CA1 neurons of a stressed
rat (bar: 20 𝜇m). The AT1R was detected with affinity-purified rabbit anti-AT1R antibodies followed by F(ab)
2
fragments of Alexa Fluor 488-
labeled (green) secondary antibodies, and hyperphosphorylated tau was visualized with affinity-purified mouse anti-PHF antibody followed
by F(ab)
2
fragments of Alexa Fluor 546-labeled secondary antibodies (red). Histological experiments are representative of 4 rats/group ((a)
and (c)).
neuroprotective NMDA receptor subtype Grin3a (NR3A)
[30, 31] was also downregulated by stress (Figure 3(b)).
Immunohistology data complemented the microarray study
and showed abundantmembrane-localizedGrin3a protein in
hippocampal CA1 neurons of a nonstressed control whereas
the neuronal Grin3a protein was barely detectable in the
hippocampal neurons of a stressed rat (Figure 3(f)). As a con-
sequence of stress-induced Grin3a (NR3A) downregulation,
glutamate excitotoxicity, for example, triggered by decreased
Gad enzyme activity, could be further augmented [30, 31].
Taken together, whole genome microarray gene expression
profiling detected signs of neurodegeneration and markers
of enhanced glutamate excitotoxicity in the hippocampus of
stressed rats.
3.4. Treatment with the Brain-Penetrating ACE Inhibitor,
Captopril, Retarded Signs of Neurodegeneration Induced by
Chronic Mild Stress. In view of the strongly upregulated
Ace protein, we asked whether treatment with the brain-
penetrating ACE inhibitor, captopril, could affect the process
of neurodegeneration triggered by stress. Aged rats were
treated with captopril during the chronic unpredictable
mild stress procedure. As a sign of neurodegeneration, we
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Figure 3: Whole genome microarray gene expression profiling detected stress-induced signs of hippocampal neurodegeneration. (a) and
(b) Whole genome microarray gene expression profiling of hippocampal gene expression documents that stress promoted the significant
downregulation of probe sets detecting neuron-specific genes with cytosolic localization (a) or membrane localization (b) according to GO
analysis. All probe sets were significantly downregulated in the hippocampus of stressed rats relative to nonstressed controls (𝑃 < 0.05 and
≥2-fold difference). The heat map visualizes signal intensities (centered to the median value). (c) Immunohistological detection of Map2
in hippocampal CA1 neurons of a stressed rat (left panel) relative to a nonstressed control (right panel; bar: 20𝜇m). (d) Hippocampal
Map2 expression level was determined by qRT-PCR and is presented as the ratio of Map2/Gapdh expression (±s.d.; 𝑛 = 4; 𝑃 = 0.0004).
(e) Hippocampal Gad activity of stressed rats relative to nonstressed controls (±s.d.; 𝑛 = 8; 𝑃 = 0.0001). (f) The decreased hippocampal
Grin3a protein level of a stressed rat (left panel) relative to that of a nonstressed control (right panel) was detected by immunohistology in
hippocampal CA1 neurons; bar: 20 𝜇m. Immunohistology data are representative of 4 rats/group ((c) and (f)).
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Figure 4: Treatment with the brain-penetrating ACE inhibitor captopril retarded signs of neurodegeneration induced by chronic mild
stress. (a) Immunohistological detection of hyperphosphorylated tau protein with anti-PHF antibody in hippocampal CA3 neurons of a
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with theACE inhibitor captopril (Stressed +ACE-I) during the stress protocol (𝑛 = 4/group). (c) Immunoblot detection of Sncg (upper panel)
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ACE-I) treatment (𝑛 = 4/group). (d) Hippocampal Gad activity of stressed rats without treatment relative to stressed rats treated with the
ACE inhibitor (Stressed + ACE-I) captopril (𝑛 = 8/group; 𝑃 = 0.0002). (e) Immunoblot detection of the amyloid beta (A4) precursor protein,
App (IB: App; upper panel), and 𝛽-amyloid (IB: Abeta; lower panel) in hippocampal extracts of stressed rats without treatment relative to
stressed rats treated with the ACE inhibitor captopril (Stressed + ACE-I) during the stress protocol (𝑛 = 4/group).
determined the hippocampal tau phosphorylation. Immuno-
histology analysis revealed a substantially decreased level
of hyperphosphorylated tau protein in hippocampal CA3
neurons of a stressed rat with captopril treatment relative to
that of a stressed control without ACE inhibitor treatment
(Figure 4(a)). Immunoblot detection of hyperphosphorylated
tau confirmed immunohistology data and demonstrated
the decreased hyperphosphorylated tau protein content in
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the hippocampus of stressed rats with captopril treatment rel-
ative to that of stressed rats without treatment (Figure 4(b)).
Concomitantly, with the decreased tau phosphorylation, the
stress-induced loss of synuclein-gamma (Sncg) was also
retarded byACE inhibition with captopril (Figure 4(c), upper
panel).
We next assessed the hippocampal Gad65 protein level
and activity. Immunoblot analysis showed that captopril
treatment counteracted the stress-induced decrease in hip-
pocampal Gad65 protein (Figure 4(c), lower panel). The
preserved Gad65 protein was accompanied by a significantly
higher hippocampal Gad activity in stressed rats with cap-
topril treatment compared to that in stressed rats without
treatment (Figure 4(d)). Taken together, our data indicate
that inhibition of ACE with a brain-permeable ACE inhibitor
retarded the stress-induced tau hyperphosphorylation and
counteracted the downregulation of Gad activity triggered by
chronic mild stress.
Previous studies indicate that chronic mild stress enhan-
ces the generation of A𝛽 as amajor neuropathological feature
of AD [12] while ACE inhibition decreases the hippocampal
A𝛽 level, as documented in a genetic AD model [20]. The
increasedA𝛽 generation could be a consequence of the stress-
induced increase in the steady-state level of the amyloid beta
(A4) precursor protein (App) [32]. Complementary to those
data, immunoblot analysis detected the high hippocampal
App load in stressed rats without treatment whereas the
hippocampal App content was substantially decreased in
stressed rats withACE inhibitor treatment (Figure 4(e), upper
panel). Concomitantly, immunoblot analysis revealed that
the hippocampal A𝛽 level was also decreased in stressed rats
with ACE inhibitor treatment compared to that in stressed
rats without treatment (Figure 4(e), lower panel).
4. Discussion
4.1. Chronic Unpredictable Mild Stress Triggered Signs of Hip-
pocampal Neurodegeneration. Our study applied the chronic
unpredictable mild stress model, which imitates major fea-
tures of sporadic AD such as tau hyperphosphorylation,
enhanced A𝛽 generation, and other signs of dendritic and
synaptic degeneration [7, 12]. In agreement with those
previous studies, we also found that chronic mild stress
triggered signs of hippocampal neurodegeneration, which
was documented by hippocampal tau hyperphosphorylation,
decreased levels of major neuronal proteins such as Map2
and Sncg, and an increased level of A𝛽-generating App.
Concomitantly, with AD-related signs of neurodegenera-
tion, glutamate excitotoxicity-enhancing features appeared
such as decreased Gad65 protein level and enzyme activity
and decreased hippocampal expression of the glutamate-
inhibitory NMDA receptor subtype, Grin3a (NR3A). The
ensuing sensitization of glutamate excitotoxicity could con-
tribute to stress-induced signs of neurodegeneration because
glutamate excitotoxicity is a major factor, which contributes
to neurodegeneration and tau hyperphosphorylation [29].
4.2. Chronic Mild Stress Induced Upregulation of Hippocampal
Ace Protein and Activity. In search for additional stimuli,
which could account for the development of stress-induced
signs of neurodegeneration, our study detected a significantly
increased hippocampal protein level of the angiotensin II-
generating enzyme, Ace. Immunohistology analysis localized
the upregulated Ace protein not only in brain vessels but also
in neuronal cell bodies of the hippocampus. Concomitantly,
an increased hippocampal Ace activity and angiotensin II
peptide level were detected.The upregulation of neuronalAce
expression and protein level could be a direct consequence of
the stress-induced activation of the hypothalamic pituitary
adrenocortical (HPA) axis because several studies found
that ACE expression was triggered by glucocorticoids and
glucocorticoid receptor activation [33–35].
4.3. ACE Inhibition Retarded Signs of Neurodegeneration
Induced by Chronic Mild Stress. The upregulated Ace protein
could be causally involved in signs of neurodegeneration
triggered by chronic mild stress because treatment with
the brain-penetrating ACE inhibitor, captopril, retarded the
development of signs of stress-induced neurodegeneration,
that is, tau hyperphosphorylation, downregulation of neu-
ronal proteins, decreased Gad enzyme activity, and increased
hippocampal App level.
The mechanism underlying the neuroprotective activity
of central ACE inhibition is not entirely understood. Several
studies indicated that the neuroprotective effect of central
ACE inhibition is largely due to a decrease in angiotensin
II generation and subsequently blunted activation of the
angiotensin II AT1 receptor, AT1R [20, 36–40]. Such con-
clusion is supported by data, which show the involvement
of angiotensin II-AT1R in major neuropathological features
such as tau hyperphosphorylation [37], enhanced glutamate
release [38], and increased A𝛽 formation [20, 39, 40]. In
addition to direct neuroprotection, inhibition of the ACE-
AT1R axis could also counteract the stress response by
blunting the release of ACTH [41]. In agreement with a role
of the ACE-angiotensin II-AT1R axis in stress-induced neu-
rodegeneration, we found that the hippocampal angiotensin
II content was increased by stress, and hippocampal neurons
with hyperphosphorylated tau protein and overt neurode-
generation were AT1R-positive.
In view of the stress-induced upregulation of the hip-
pocampal Ace and the neuroprotective activity of ACE inhi-
bition in the chronic mild stress model, our data support a
causative role of ACE in stress-induced neurodegeneration.
Because the model reproduces major features of sporadic
AD (i.e., tau hyperphosphorylation, A𝛽 generation, and
glutamate excitotoxicity), our study could provide a rationale
for the documented efficacy of centrally activeACE inhibitors
in several clinical studies, which showed retardation of AD-
related cognitive decline as amajor sign of neurodegeneration
[21–25]. In this context, the suggested repurposing of ACE
inhibitors for clinical conditions related to AD and other
types of dementia [42] could be a potential option, which
deserves further study.
BioMed Research International 9
5. Conclusion
Inhibition ofACEwith the centrally acting captopril retarded
the development of hippocampal tau phosphorylation, signs
of neurodegeneration, and amyloid beta (A4) precursor
protein (App) upregulation in rats subjected to chronic
unpredictable mild stress, as a model, which reproduces
major pathological features of sporadic AD.
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